TNF and prostate adenocarcinoma: However, the mRNA expression levels of FASLG in LUSC; MLKL in LUSC; RIPK1 in COAD; TNF in prostate adenocarcinoma (PRAD) and liver hepatocellular carcinoma (LIHC); FAS in LUSC, COAD, KICH, PRAD, and bladder urothelial carcinoma (BLCA); RIPK3 in LUSC, COAD, KICH, PRAD, and HNSC; and TLR3 in LUSC, COAD, KICH, PRAD, BRCA, HNSC, LIHC, STAD, and THCA were significantly downregulated (Figure 1B).